Brainsway (BWAY) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

BWAY Brainsway

Watchlist

9.680
-0.030-0.31%

Close Nov 27 16:00 ET

9.680
0.0000.00%

Post 20:01 ET

181.82MMarket Cap121.00P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

BrainsWay's Deep TMS Shows Promise in Pain Reduction
TipRanksNov 20 10:41 ET
BrainsWay Announces The Publication Of Feasibility Clinical Data Evaluating The Analgesic Effects Of Deep Transcranial Magnetic Stimulation In Patients With Peripheral Neuropathic Pain. The Results Were Published In The Neuromodulation Journal, In A...
BenzingaNov 20 08:26 ET
Express News | Brainsway Reports Promising Feasibility Data Showing Pain Reduction With Deep Tms Therapy
ReutersNov 20 08:00 ET
Express News | Jonathan Shulkin Reports 19.1% Stake in Brainsway Ltd as of Nov 5 - SEC Filing
ReutersNov 13 18:14 ET
Ladenburg Thalmann Maintains Brainsway(BWAY.US) With Buy Rating, Raises Target Price to $13.4
Moomoo NewsNov 13 09:33 ET · Ratings
Brainsway Price Target Raised to $13.40 From $12.60 at Ladenburg
TipRanksNov 13 08:37 ET

Comments

Jaguar8

Nov 20 07:06

NEWS

$Brainsway (BWAY.US)$
BrainsWay Reports Promising Feasibility Data Showing Pain Reduction with Deep TMS Therapy
BrainsWay (NASDAQ & TASE: BWAY) announced positive feasibility clinical data for their Deep TMS™ therapy in treating peripheral neuropathic pain. The double-blind, randomized crossover trial involved 17 patients who received either active Deep TMS or sham treatment for five days, followed by a nine-week washout period before switching treatments. Results demonstrated significant r...

Jaguar8

Jun 17 06:37

NEWS

$Brainsway (BWAY.US)$
BrainsWay Expands Global Imprint with Exclusive Multi-Year Distribution Agreement in Canada
BrainsWay has announced an exclusive multi-year distribution agreement to market its Deep Transcranial Magnetic Stimulation (Deep TMS) system in Canada. The agreement involves a specialty distributor serving acute and non-acute healthcare sectors, and includes minimum quantity orders, starting with 11 systems in 2024. BrainsWay’s CEO, Hadar Levy, emphasized the significance of exp...

Jaguar8

Jun 3 06:35

NEWS

$Brainsway (BWAY.US)$
BrainsWay Receives Expanded FDA Labeling to Treat Late Life Depression
BrainsWay has announced that the FDA has expanded the indication for its Deep Transcranial Magnetic Stimulation system (Deep TMS™) to treat major depressive disorder (MDD) in patients aged 22 to 86, extending beyond the previous age limit of 68. This marks the company's 10th FDA clearance, making their Deep TMS the only TMS device approved for depression treatment in patients over 68. The expanded lab...

Stock Region

Mar 28 17:48

Medical Technology Company Reveals Promising Outcomes For Depression Treatment

A Glimmer of Hope: Revolutionizing Late-Life Depression Treatment with Deep TMS Technology.
Depression is a formidable adversary at any age, but it poses unique challenges for the elderly. Traditional treatments often fall short, leaving a gap that demands innovative solutions. Enter Deep Transcranial Magnetic Stimulation (Deep TMS) technology, a beacon of hope for those battling late-life depression. Recent findings f...